Back

Ventriculo-arterial coupling in patients with wild-type transthyretin cardiac amyloidosis treated with tafamidis

17 May 2025 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: Multimodal imaging and hemodynamic assessment in amyloidosis and heart failure Imaging HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Valeria Anna Di Simone

Foundation IRCCS Policlinic San Matteo - University of Pavia, Pavia (Italy)

6 More presentations in this session

Presentation thumbnail
Late life echocardiographic effects of the amyloidogenic V142I transthyretin variant
Doctor S. Selvaraj (Durham, US)
Abstract Slides Video
Presentation thumbnail
Prognostic value of left atrial strain in patients with transthyretin amyloid cardiomyopathy
Doctor E. Tan (Singapore, SG)
Abstract Slides Video
Presentation thumbnail
Right ventricular-pulmonary artery uncoupling and strain in acute heart failure
Associate Professor A. Palazzuoli (Siena, IT)
Abstract Slides Video
Presentation thumbnail
The usefulness of liver stiffness measurement via transient elastography in predicting right atrial pressure and clinical outcomes in heart failure: a multicenter study
Doctor K. Kajitani (Osaka, JP)
Abstract Slides Video
Presentation thumbnail
Impact of cardiac magnetic resonance on the diagnosis of cardiac sarcoidosis - a 15-year experience
Doctor N. Ojrzynska-Witek (Warsaw, PL)
Abstract Slides Video

Access the full session

Session thumbnail
Multimodal imaging and hemodynamic assessment in amyloidosis and heart failure

The Event

Event poster

Heart Failure 2025

17 May - 20 May 2025
You may be interested in
thumbnail
Congress Presentation
Impairment of right ventricular to pulmonary artery coupling is associated with worse survival in cardiac amyloidosis
thumbnail
Congress Presentation
Right ventricular to pulmonary artery uncoupling is an early predictor of poor outcome in wild-type transthyretin cardiac amyloidosis
thumbnail
Congress Presentation
RV-PA uncoupling is a strong predictor of 3-year all-cause mortality in transthyretin amyloid cardiomyopathy.

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources